E
Edna F. Choo
Researcher at Genentech
Publications - 65
Citations - 3912
Edna F. Choo is an academic researcher from Genentech. The author has contributed to research in topics: Pharmacokinetics & Cobimetinib. The author has an hindex of 28, co-authored 63 publications receiving 3565 citations. Previous affiliations of Edna F. Choo include St. Jude Children's Research Hospital & Pfizer.
Papers
More filters
Journal ArticleDOI
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Richard B. Kim,Richard B. Kim,Brenda F. Leake,Brenda F. Leake,Edna F. Choo,Edna F. Choo,George K. Dresser,George K. Dresser,Samir V. Kubba,Samir V. Kubba,Ute I. Schwarz,Ute I. Schwarz,Amanda Taylor,Amanda Taylor,H. G. Xie,H. G. Xie,Joel McKinsey,Joel McKinsey,Sheng Zhou,Sheng Zhou,Lu-Bin Lan,Lu-Bin Lan,John D. Schuetz,John D. Schuetz,Erin G. Schuetz,Erin G. Schuetz,Grant R. Wilkinson,Grant R. Wilkinson +27 more
TL;DR: Allelic variation in MDR1 is more common than previously recognized and involves multiple SNPs whose allelic frequencies vary between populations, and some of these SNPs are associated with altered P‐glycoprotein function.
Journal ArticleDOI
The impact of p-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/ 1b knockout mouse model
Angela C. Doran,R. Scott Obach,Bill J. Smith,Natilie Hosea,Stacey L. Becker,Ernesto Callegari,Cuiping Chen,Xi Chen,Edna F. Choo,Julie Cianfrogna,Loretta M. Cox,John P. Gibbs,Megan A. Gibbs,Heather L. Hatch,Cornelis E. C. A. Hop,Ilana N. Kasman,Jennifer L. LaPerle,JianHua Liu,Xingrong Liu,Michael J. Logman,Debra Maclin,Frank M. Nedza,Frederick R. Nelson,Emily R. Olson,Sandhya Rahematpura,David Raunig,Sabrinia Rogers,Kari Schmidt,Douglas K. Spracklin,Mark A. Szewc,Matthew D. Troutman,Elaine E. Tseng,Meihua Tu,Jeffrey Van Deusen,Karthik Venkatakrishnan,Gary Walens,Ellen Q. Wang,Diane Wong,Adam Yasgar,Chenghong Zhang +39 more
TL;DR: It appears that most CNS-active agents demonstrate at least some P-gp-mediated transport that can affect brain concentrations, and unbound plasma concentrations may need to be greater than values projected using receptor affinity data to achieve adequate receptor occupancy for effect.
Journal Article
Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes
Edna F. Choo,Brenda F. Leake,Christoph Wandel,Hitoshi Imamura,Alastair J. J. Wood,Grant R. Wilkinson,Richard B. Kim +6 more
TL;DR: Findings provide "proof-of-concept" for increasing HIV protease inhibitor distribution into pharmacologic sanctuary sites by targeted inhibition of P-glycoprotein using selective and potent agents and suggest a new therapeutic strategy to reduce HIV-1 viral replication.
Journal ArticleDOI
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Ted Lau,Emily Chan,Marinella Callow,Jo Waaler,Jason Boggs,Robert A. Blake,Steven Magnuson,Amy Sambrone,Melissa Schutten,Ron Firestein,Ondrej Machon,Vladimir Korinek,Edna F. Choo,Dolores Diaz,Mark Merchant,Paul Polakis,Daniel D. Holsworth,Stefan Krauss,Mike Costa +18 more
TL;DR: A potent and specific small-molecule tankyrase inhibitors are developed that reduce Wnt/β-catenin signaling by preventing poly(ADP-ribosyl)ation-dependent AXIN degradation, thereby promoting β- catenin destabilization and establishing proof-of-concept antitumor efficacy for tankyrases in APC-mutant CRC models.
Journal ArticleDOI
Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
Klaus P. Hoeflich,Sylvia Herter,Janet Tien,Leo Wong,Leanne Berry,Jocelyn Chan,Carol O'Brien,Zora Modrusan,Somasekar Seshagiri,Mark R. Lackner,Howard M. Stern,Edna F. Choo,Lesley J. Murray,Lori Friedman,Marcia Belvin +14 more
TL;DR: The biological properties of GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor, are reported and the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition are increased and have implications for therapeutic intervention in the clinic.